COGSTATE LTD — Investor Presentation 2013

Aug 14, 2013

==> picture [114 x 101] intentionally omitted <==

ASX Announcement

Thursday 15[th] August 2013

2013 Full Year Financial Results – Notice of Investor Conference Call

Cogstate (ASX.CGS) will lodge its Appendix 4E and Full Year Financial Results for the period ended June 30, 2013 on Wednesday August 21.

An investor conference call, hosted by Brad O’Connor, Chief Executive will be held at 2.30pm AEST, on this day, and can be accessed via the dial in details below.

Conference ID: 29435054

Toll free dial in numbers

Australia: 1800 123 296 New Zealand 0800 452 782 United States 1855 293 1544 Canada 1855 5616 766 Hong Kong 800 908 865 Singapore 800 616 2288 China 4001 203 085 United Kingdom 0808 234 0757 India 1800 3010 6141 Japan 0120 985 190

From all other international locations dial: Toll: + 61 2 8314 8370 (standard call charges apply)

A recording of the call will be made available at www.openbriefing.com

ENDS

For further information contact:

Kyahn Williamson Brad O’Connor Buchan Consulting CogState Chief Executive Officer +61 3 9866 4722 or 0401 018 828 +61 3 9664 1300 or 0411 888 347 kwilliamson@buchanwe.com.au boconnor@cogstate.com

About CogState

CogState Ltd (ASX: CGS) is a multi-faceted cognitive assessment and training company, focused on the development and commercialisation of rapid, computerised tests of cognition (brain function). It has three distinct business units:

Clinical Trials: In the clinical drug trial market, CogState technology and associated services are used by pharmaceutical and biotechnology companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials. Since sales into the clinical trials market began in 2004, CogState has secured agreements with top pharmaceutical companies including Pfizer, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Novartis, Lundbeck, Dainippon Sumitomo, Targacept, Otsuka, and Servier.

Axon Sports: The mission of Axon Sports is to “protect and train the athletic brain”. Axon’s focus is to research, develop and deliver cutting edge tools to assess, monitor and improve the athletic brain.

Axon has been developing sport specific training products, initially focussed on American football and baseball, and the resulting technologies have now been launched within a small number of elite US college programs. In addition, the first of Axon’s consumer iPad apps was launched in 2012.

In the area of sports related concussion, CogState’s technology has been used by a number of highly regarded institutions and sporting organisations around the world for almost 10 years. That technology is now marketed to consumers as Axon Sports. Current users of CogState/Axon Sports in Australia include the AFL and NRL, whilst in the USA elite programs such as the NBA, WNBA, NHL as well as college programs such as University of Notre Dame, University of Michigan and University of Connecticut all use the Axon Sports system.

Healthcare: In the primary care or general practice setting, the CogState’s COGNIGRAM ™ assesses cognition in patients and the reports generated on the basis of this assessment can allow physicians to identify subtle changes that could be indicative of the early stage of a neurodegenerative disease, such as Alzheimer’s disease. CogState intends to develop COGNIGRAM ™ to monitor changes in cognitive function following concussion or after treatment with drugs or other types of interventions. In June 2012, CogState entered into an agreement with Merck Canada Inc. providing it with the exclusive right to market and promote COGNIGRAM ™ in Canada.